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The HIV-1 encoded accessory protein, viral protein R (Vpr) is responsible for several biological effects in HIV-1-infected
cells including nuclear transport of the preintegration complex, activation of long terminal repeat (LTR)-mediated transcrip-
tion, and the induction of cell-cycle arrest and apoptosis. Vpr’s ability to arrest cells at the G2 phase of the cell cycle is due
to the inactivation of p34cdc2 cyclin B complex, resulting in hypophosphorylation of substrates involved in cell-cycle
progression from G2 to mitosis (M). Poly(A) polymerase (PAP), the enzyme responsible for poly(A) addition to primary
transcripts, contains multiple consensus phosphorylation sites for p34cdc2 cyclin B kinase that regulates its catalytic activity.
We investigated the effects of Vpr on the activity of PAP in Jurkat cells using a superinfection system. Superinfection of cells
using Vpr1 vesicular stomatitis virus G protein (VSV-G)-pseudotyped virus caused a complete dephosphorylation of PAP.
Cotransfection studies in 293T cells and Xenopus oocyte RNA injection experiments mirrored these effects. Vpr’s dramatic
effect on PAP dephosphorylation was reflected in enhanced polyadenylation activity in PAP activity assays. HIV-1 Vpr appears
to enhance processes that are coupled to transcription such as polyadenylation and could ultimately prove to optimize HIV-1
replication and contribute to HIV-1 pathogenesis. © 2002 Elsevier Science
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The HIV-1 encoded accessory protein, viral protein R
(Vpr), is incorporated into viral particles, suggesting that
it has functional importance early in infection. Indeed,
Vpr functions early in infection to induce G2 cell-cycle
arrest and mediate the nuclear import of the HIV-1 pre-
integration complex (Emerman, 1996; Mahalingam et al.,
1998; Planelles et al., 1996; Poon et al., 1998; Re and
Luban, 1997; Stewart et al., 1997; Stivahtis et al., 1997). In
addition, several other biological roles for Vpr have been
described and these include the activation of long-termi-
nal repeat (LTR)-mediated transcription (Agostini et al.,
1996; Yao et al., 1998), the induction of apoptosis (Conti et
al., 2000, 1998), and an implication in reverse transcrip-
tase fidelity (Mansky, 1996). Recent evidence also sug-
gests that Vpr may perturb RNA metabolism by blocking
RNA export as shown in yeast (Gu et al., 1997; Vodicka et
al., 1998). The mechanisms by which Vpr mediates these
latter functions remain to be fully characterized, however.
Vpr is not essential for HIV-1 replication in tissue culture
systems; nevertheless, these Vpr effects appear to con-
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321tribute significantly to the enhancement of HIV-1 patho-
genesis (Cullen, 1998; Emerman and Malim, 1998; Sub-
bramanian and Cohen, 1994).
Vpr’s ability to cell-cycle arrest at the G2 phase of the
cell cycle is mediated by the inactivation of a cyclin-
dependent kinase, p34cdc2 cyclin B complex, resulting in
hypophosphorylation of substrates involved in cell-cycle
progression from G2 to mitosis (M). Arrest at the G2
phase has been shown to enhance LTR-driven transcrip-
tion, suggesting that Vpr creates an environment in
which viral gene transcription is favored (Goh et al., 1998;
Hrimech et al., 1999). We (Yao et al., 1998) and others
(Gozlan et al., 1998) have shown that the enhancement of
HIV-1 transcription is modest, reaching about fivefold in
experimental settings. This enhancement may be
enough to sustain a replicative advantage in host cells,
but also may require the action of Tat or other factors to
sustain it (Hrimech et al., 1999).
Poly(A) polymerase (PAP) is the enzyme primarily re-
sponsible for poly(A) addition to primary transcripts in
the nucleus. In the carboxyl-terminus, PAP contains mul-
tiple consensus and nonconsensus phosphorylation
sites for p34cdc2 cyclin B kinase and is a substrate for this
and other kinases (Bond et al., 2000; Colgan et al., 1996,
1998). The phosphorylation status of PAP modulates its
activity with the nonphosphorylated protein being the
most active (Colgan et al., 1998). While it is clear that
0042-6822/02 $35.00
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322 MOULAND ET AL.completely phosphorylated PAP has negligible poly(A)
addition activity, functional differences between differen-
tially phosphorylated forms of PAP are not so clear-cut
(Bond et al., 2000). There is a gradient of PAP phosphor-
ylated species indicating that the extent to which each is
phosphorylated may determine function within the cell
(Kyriakopoulou et al., 2001; Zhao and Manley, 1998) and
during the cell cycle (Bond et al., 2000). Hyperphosphor-
ylation of p34cdc2 cyclin B kinase is a consequence of
cell-cycle progression to M phase resulting in PAP hy-
perphosphorylation and is coincident with a suppression
of protein and RNA synthesis during cell division (Bon-
neau and Sonenberg, 1987; Colgan et al., 1996, 1998).
We investigated the influence of Vpr on the activity of
PAP in superinfected Jurkat cells using VSV-G
pseudotyped HIV-1 virus. Superinfection of cells using
Vpr2 and Vpr1 virus demonstrated a specific effect of
Vpr on nuclear and whole-cell PAP phosphorylation sta-
tus. Remarkably, we observed a complete dephosphor-
ylation of PAP due to the expression of Vpr early postin-
fection. Cotransfection studies in 293T cells and coinjec-
tion experiments using Xenopus oocytes mirrored these
effects on PAP phosphorylation status. Results from poly-
adenylation activity assays demonstrated increased PAP
activity in fractionated infected cells due to Vpr. In vitro
studies explored the result of PAP dephosphorylation on
HIV-1 RNA metabolism and poly(A) tail length. Whereas
PAP activity was enhanced, neither the 39 poly(A) tail
length nor the mRNA half-life was markedly altered. Vpr
not only appears to have a direct transactivation function,
but can have downstream effects on closely coupled
gene regulation steps involving 39-end processing, a
step that is now appreciated to be tightly coupled to
transcription (Calvo and Manley, 2001; Dantonel et al.,
1997; Hirose and Manley, 1998; McCracken et al., 1997;
Zhao et al., 1996).
RESULTS
Vpr-mediated hypophosphorylation of poly(A)
polymerase
Figure 1A shows the phosphorylation status of PAP in
nuclear extracts from mock control, Vpr2, Vpr1, and
R80AVpr VSV-G-pseudotyped virus-infected Jurkat cells. In
both Jurkat and HeLa (not shown) cells, two to three PAP
isoforms were observed ranging in molecular weight
from 97 to 105 kDa. Higher molecular weight forms rep-
resent the phosphorylated species (PPAP). The dephos-
phorylated form of PAP is known to be catalytically ac-
tive, as phosphorylation negatively affects activity (Col-
gan et al., 1998). In Vpr2, R80AVpr, and mock virus-infected
cells, PAP is found as several bands on SDS gels, dem-
onstrating that a distribution of PAP activity is found in
these cells (Zhao and Manley, 1998). In Vpr1 virus-
infected cells, however, the predominant PAP is in a
completely hypophosphorylated state, suggesting a spe-cific effect of HIV-1 Vpr on PAP phosphorylation. Since
p34cdc2 kinase activity is negatively affected by Vpr, and
PAP is a substrate for p34cdc2 kinase on multiple consen-
sus and nonconsensus sites, this result was not entirely
surprising. However, the dramatic difference in phos-
phorylation status of PAP mediated by Vpr in infected cell
preparations was not at all expected. The R80AVpr mutant,
a mutant that does not cause cell-cycle arrest (Yao et al.,
1998), generated a PAP phosphorylation status identical
to that in mock- and Vpr2 virus-infected cells. A time-
course experiment was performed on whole-cell extracts
(Fig. 1B). As early as 6 h p.i. PAP is dephosphorylated via
virion-associated Vpr. As a control for PAP phosphoryla-
tion, nocodazole was used to cause M phase arrest in
which PAP becomes completely hyperphosphorylated as
described before (Figs. 1B and 1C) (Colgan et al., 1996;
Hirose and Manley, 1998). Thus, the cell-cycle arrest
phenotype by Vpr correlates well with G2 arrest. Using
FIG. 1. Vpr mediates PAP dephosphorylation. (A) Nuclear extracts
were prepared from mock, Vpr2, Vpr1, and R80AVpr-superinfected
Jurkat cells at 20 h p.i. as described under Materials and Methods.
Equal quantities of protein were loaded onto 7.5% SDS–PAGE and
transferred to nitrocellulose. Blots were probed with anti-PAP. (B) Time
course of PAP dephosphorylation due to Vpr. Jurkat cells were infected
as above with Vpr1 pseudotyped virus. At 0, 6, and 12 h p.i., whole-cell
extracts were prepared and PAP was analyzed as above. As early as
6 h p.i., PAP dephosphorylation becomes apparent. Nocodazole treat-
ment caused hyperphosphorylation of PAP (PPAP) as described before.
(C) Cell-cycle analysis of mock, Vpr2, Vpr1, and nocodazole-treated
Jurkat cells. Note Vpr1 virus caused cell-cycle arrest in G2, and
nocodazole treatment blocks cells in M phase. Scale is identical for all
FACS panels. Annexin V apoptosis assay showed Vpr-mediated apo-
ptosis at 20 h postinfection (not shown). Apoptosis is not observed
before this time (not shown). The results shown are representative of
three experiments. PAP, dephosphorylation form of PAP; PPAP, major
phosphorylated form of PAP.whole-cell extracts, we routinely observed one principal
PAP band, while two to three PAP-specific bands were
323HIV-1 Vpr AND POLY(A) POLYMERASE PHOSPHORYLATIONobserved in blots using nuclear extracts. The reasons for
this difference are unclear but could reflect the extraction
method used.
Apoptosis was assessed by Annexin V staining; this
was only apparent in superinfected Vpr1 and becomes
apparent only after 20 h (data not shown; Yao et al., 1998).
To determine whether the effects of Vpr on PAP phos-
phorylation could be observed during transient expres-
sion, Vpr was coexpressed with PAP using EukPAP and
SVCMV-Vpr expression plasmids in 293T cells (Figs. 2A
FIG. 2. Vpr mediates PAP dephosphorylation in 293T cells and
Xenopus oocytes. (A) 293T cells were mock transfected or transfected
with EukPAP (PAP) or EukPAP and SVCMV-Vpr (PAP1Vpr) or SVCMV-
Vpr (Vpr). PAP and Vpr were sequentially immunoprecipitated from
lysates in RIPA buffer or immunoprecipitated using a preimmune rabbit
serum (PI). Cotransfection of EukPAP and SVCMV-Vpr caused a fraction
PAP to migrate faster, likely due to dephosphorylation of PAP mediated
by coexpressed Vpr. (B) Vpr expression was confirmed in SVCMV-Vpr
and SVCMV-Vpr and EukPAP transfections (bottom). (C) Xenopus laevis
oocytes were injected with water (mock), PAP RNA, Vpr RNA, or coin-
jected with Vpr and PAP RNAs. PAP RNA-injected oocytes were left
untreated (2) or induced to mature by the addition of progesterone (1).
Oocytes were processed as described under Materials and Methods
and PAP and Vpr were sequentially immunoprecipitated from oocyte
lysates. Progesterone treatment induced PAP phosphorylation (PPAP);
however, when Vpr was coexpressed (PAP1Vpr RNA) and subse-
quently induced to mature with progesterone, PAP phosphorylation
was blocked. Vpr expression in oocytes was confirmed on the right.
The results shown are representative of two to three experiments.and 2B) followed by metabolic labeling. PAP expression
alone yielded a single immunoreactive band at approxi-mately 100 kDa, while coexpression of Vpr and PAP in
293T cells caused the appearance of a lower apparent
molecular weight PAP consistent with dephosphorylation
of a portion of endogenous and overexpressed PAP (Fig.
2A). The proportion of PAP in a dephosphorylated state
was not as marked as that presented in Fig. 1 likely
because the efficiency of transfection was markedly re-
duced compared to the superinfection efficiency that
was routinely 95–100%. Figure 2B shows the level of
expression of Vpr in EukPAP and SVCMV-Vpr-transfected
cells.
The Vpr-induced PAP dephosphorylation was also
tested in RNA injection experiments using Xenopus lae-
vis oocytes to further substantiate Vpr’s effect on PAP
phosphorylation. In Xenopus oocytes, injected PAP RNA
yields a 97-kDa band. When PAP RNA is injected into
oocytes that are induced to mature with progesterone,
PAP become hyperphosphorylated (Fig. 2C). When both
PAP and Vpr RNAs are coinjected, and then induced to
mature with progesterone, Vpr expression prevented the
maturation-induced hyperphosphorylation of PAP (Fig.
2C). This indicates that Vpr can modulate a specific
phosphorylation activity or phosphatase activity on PAP
protein. Figure 2D demonstrates the expression levels of
Vpr in injected oocytes.
Vpr modestly enhances steady-state HIV-1 RNA
levels without a concomitant effect on RNA stability
Because PAP activity was dramatically enhanced in
Vpr1-infected cells, we reasoned that the poly(A) tail
length of HIV-1 mRNAs could be increased accordingly
and as a result HIV-1 RNA stability be increased. mRNA
stability measurements were performed using the tran-
scription inhibitor, Actinomycin D. Figure 3 shows the
results of the mRNA stability estimations at 20 h p.i. This
represents the time at which cell-cycle analysis was
performed and nuclear and whole-cell extracts were
prepared (cf. Figs. 1 and 2). At 20 h p.i. (time 0 in Fig. 3),
we observed the expected modest stimulation of steady-
state HIV-1 mRNA levels as we have shown previously
(Yao et al., 1998). The RNA half-lives were determined for
the unspliced, singly spliced, and multiply spliced HIV-1
mRNA species and these were found to be approxi-
mately equivalent, of about 5–6 h (bottom panel) in both
Vpr2 and Vpr1-superinfected cells. Cellular GAPDH,
whose mRNA half-life is greater than 24 h (Mouland and
Hendy, 1991), was used to control for RNA loading. We
did observe, however, that when the signal intensities for
each size class of HIV-1 mRNA was compared at time 0,
Vpr expression slightly altered the ratio of unspliced to
spliced RNA species (see histogram insets).
Vpr has no effects on HIV-1 poly(A) tail lengthsSince there were no apparent changes in HIV-1
mRNA stability, which is anyhow not always accompa-
RNA s
324 MOULAND ET AL.nied with increased poly(A) tail lengths (Richter, 1996),
examination of the length of the poly(A) tail of HIV-1
transcripts was warranted. An RNAseH assay was
used to estimate poly(A) tail length of all HIV-1 tran-
scripts with the use of an antisense DNA oligomer to
a common region of HIV-1 transcripts. Cytosolic RNA
was isolated from superinfected cells at 20 h p.i. and
incubated with an antisense oligomer to the 39-UTR
region of HIV-1 mRNAs as described under Materials
FIG. 3. Vpr modestly enhances steady-state HIV-1 RNA levels, but doe
virus as described under Materials and Methods to result in 95–98%
Actinomycin D (Act D). At 0, 3, and 6 h after treatment, cytosolic RNA
transferred to nylon, and probed with a 32P-labeled 285-bp probe to the 5
RNAs. The blot was subsequently probed for GAPDH mRNA. 28S and 18
RNA was quantitated by laser scanning densitometry and related to th
intensities were plotted versus time, with HIV-1 RNA at time 0 set to 10
Vpr of each RNA species at time 0. No marked effects of Vpr on m
experiments.and Methods. Following digestion with RNAseH, the
protected fragment was separated on a denaturingagarose gel followed by blotting onto nitrocellulose
membranes. Probing of the RNA with a 32P-labeled
DNA to the Gag leader sequence revealed that the
poly(A) tail length of HIV-1 RNAs was not affected
when Vpr was expressed, and this was found to be
approximately 250 bp long (Fig. 4). The modest en-
hancement of Vpr-induced steady-state levels of RNA
were observed as before (Fig. 3 and Yao et al., 1998).
Actin and GAPDH poly(A) tail lengths were also deter-
ffect mRNA stability. Jurkat cells were superinfected with Vpr1 or Vpr2
on. Twenty hours postinfection, cells were washed and treated with
repared. (A) RNAs were loaded onto 1% agarose/formaldehyde gels,
f HIV-1 RNA to detect unspliced (9 kb) and unspliced (4 and 2 kb) HIV-1
s were revealed by ultraviolet transillumination. Each species of HIV-1
l obtained with GAPDH mRNA at each time point. The relative signal
togram insets indicate fold induction of the signal intensity caused by
tability were observed. The results shown are representative of twos not a
infecti
was p
9UTR o
S rRNA
e signa
0%. Hismined in this assay and remained unchanged with Vpr
treatment (data not shown).
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infected cells is reflected in an increase in
polyadenylation activity iv vitro
We then measured the poly(A) addition activity in vitro
using purified PAP from superinfected Jurkat cells (mock,
Vpr2, Vpr1, and R80AVpr) in a nonspecific poly(A) assay.
Data in Fig. 5 demonstrate that there is an enhancement
of adenosine triphosphate addition in Vpr1-infected
cells. The effect on poly(A) activity using extracts from
Vpr2 virus was identical to that of the R80AVpr (data not
shown). To rule out differences in PAP activity between
gel elution fractions (see Materials and Methods), ali-
quots from fractions surrounding the peak eluate were
included in the assay. In each case all the fractions from
a given condition showed similar phenomena, i.e., non-
peak eluates from Vpr1-infected cells showed enhanced
PAP activity than mock or Vpr2 virus (data not shown).
DISCUSSION
In this study we have provided evidence that PAP
FIG. 4. Vpr’s effect on PAP dephosphorylation does not influence
HIV-1 poly(A) tail length. Jurkat cells were mock infected or superin-
fected with Vpr1 or Vpr2 virus as described under Material and
Methods. Twenty hours postinfection, cells were washed and cytosolic
RNA was prepared. Equal quantities of RNA were used in RNAse H
assays as described in the text to approximate poly(A) tail length of
HIV-1 RNAs. Reaction products were loaded onto 2% agarose/formal-
dehyde gels, transferred to nylon membranes, and probed with a
32P-labeled oligomer to the 59UTR of HIV-1 RNA upstream of the major
splice donor. Vpr modestly enhanced RNA levels, but had no marked
effect on poly(A) tail length of HIV-1 RNA (indicated by arrowhead).
Poly(A) tails were approximately 250 nt in length. The results shown are
representative of two experiments.activity in HIV-1 infected cells is modulated by the HIV-1
auxiliary protein, Vpr. PAP is shown here to becomealmost completely dephosphorylated when HIV-1 Vpr is
expressed by using whole-cell and nuclear extracts,
transient transfections, and in vivo metabolic labeling. In
injected Xenopus oocytes, Vpr also blocks the matura-
tion-specific phosphorylation of PAP in progesterone-
induced Xenopus oocytes. PAP dephosphorylation is
likely to be initiated by the immediate-early effects of Vpr
(Hrimech et al., 1999), mediated at least in part by the
virion-associated Vpr since PAP dephosphorylation is
observed as early as 6 h postinfection (Fig. 1B), before
de novo synthesis of viral proteins (Reddy and Yin, 1999).
Moreover, because PAP phosphorylation is only affected
in late M phase of the cell cycle (J. Manley, Columbia
University, personal communication), the effects on PAP
phosphorylation status could not be a consequence of a
Vpr-mediated G2 arrest. While Vpr modulates p34cdc2
kinase activity and PAP is a substrate for this kinase, the
magnitude of PAP dephosphorylation due to Vpr was
FIG. 5. Vpr enhances poly(A) polymerase (PAP) activity in superin-
fected Jurkat cells. Jurkat cells were mock infected or superinfected
with Vpr1 or Vpr2 virus. Twenty hours postinfection, cells were
washed and nuclear extracts of cells were prepared. PAP was crudely
purified by column chromatography. Equal quantities of protein were
used in PAP activity assays as described under Materials and Meth-
ods. Reaction products were loaded onto 6% denaturing polyacryl-
amide/urea gels and exposed to film. Polyadenylated RNA species
(PAn) were identified by high molecular weight smears in most lanes,
except in the RNA lane where only water was added in the reaction
mixture. Vpr is shown here to markedly enhance PAP activity. The
results shown are representative of four experiments.
326 MOULAND ET AL.completely unexpected. In Fig. 1, we identify at least
three major PAP isoforms in nuclear extracts. Vpr causes
a complete loss of the two phosphorylated, higher mo-
lecular weight species (Fig. 1A) (Thuresson et al., 1994).
PAP contains multiple cdk consensus and nonconsen-
sus sites in the carboxyl-terminal region (Colgan et al.,
1996, 1998). While it is clear that cyclins A and B kinases
can phosphorylate several of these sites, other kinases
are also believed to be involved (Zhao and Manley, 1998).
As is the case for SR proteins during splicing (Cao et al.,
1997; Gui et al., 1994; Xiao and Manley, 1997), phosphor-
ylation of PAP will likely prove to be critical for function.
However, a complete picture of the importance of each of
the PAP species remains to be drawn.
Phosphorylation is central to many biological pro-
cesses including transcription, splicing, nucleocytoplas-
mic transport, and translation. For PAP, phosphorylation
has been shown to be critical by several measures.
Phosphorylation levels determine PAP’s activity during
the cell cycle (Colgan et al., 1996, 1998) and the local-
ization of the active (dephosphorylated) form of PAP is
localized to specific regions of active RNA synthesis
within the nucleus (Schul et al., 1998). Furthermore, a
phosphorylation mutant of PAP was recently shown to be
highly deleterious to cell growth (Zhao and Manley,
1998). More recent data provide evidence that PAP’s
interactions with cyclins modulate PAP phosphorylation
(Bond et al., 2000), indicating that protein interactions
with cyclins are important for function. The carboxy-
terminal region of PAP is responsible for several interac-
tions that control polyadenylation activity (Gunderson et
al., 1998, 1997). It will be interesting to assess if HIV-1 Vpr
can upset PAP’s interactions, thereby preventing PAP
phosphorylation in HIV-1-infected cells.
When PAP activity was tested in vitro in nuclear ex-
tracts, a dramatic increase in poly(A) addition activity
was observed (Fig. 5). We then examined potential con-
sequences of this enhanced PAP activity due to PAP
dephosphorylation, but this was not reflected in differ-
ences in HIV-1 RNA poly(A) tail length (Fig. 4) nor did it
produce HIV-1 transcripts with altered stability (Fig. 3). In
light of Vpr’s transactivation function (Forget et al., 1998),
its capacity to bind basal transcription factors such as
TFIIB and p300 (Agostini et al., 1996; Felzien et al., 1998)
and to mediate G2 arrest in infected cells, we tested the
effects of overexpressing PAP on Vpr transactivation and
G2 arrest in transient transfection studies but these stud-
ies did not reveal anything about the influence of PAP
activity at these levels (not shown).
Polyadenylation requires an ordered assembly of com-
ponents that includes poly(A)-binding protein (PABP),
cleavage/polyadenylation specificity factor (CPSF), and
PAP on the RNA (Colgan and Manley, 1997). Phosphor-
ylation of proteins is known to influence both RNA and
protein interactions (Idriss et al., 1994; Tacke et al., 1997;
Xiao and Manley, 1997). These types of associations arealso critical to poly(A) tail elongation (Wahle, 1995). It is
possible that PAP dephosphorylation would favor the
binding or the association between it and HIV-1 RNA, or
with proteins involved in the polyadenylation process
(Gilmartin et al., 1995; Murthy and Manley, 1995). CPSF is
known to bind PAP (Murthy and Manley, 1995) and this
association might favor polyadenylation activity in the
infected cell. Indeed, U1A-CPSF binding stabilizes CPSF
binding on RNA substrates (Lutz et al., 1996), and in
HIV-1, cyclinT1-Tat binding positively influences HIV-1
TAR RNA binding (Ivanov et al., 1999; Wei et al., 1998). As
a result of these stabilized interactions, elongation of the
poly(A) tail may be facilitated. Since we do not detect any
change in HIV-1 RNA poly(A) tail length or RNA turnover,
this model would dictate that polyadenylation is facili-
tated by Vpr due to its influence on PAP phosphorylation
status. More refined studies to examine this possibility
will be required.
PAP dephosphorylation is tightly coupled to the pre-
vention of apoptosis in several cell types in which PAP
dephosphorylation is an early event that precedes DNA
fragmentation (Atabasides et al., 1998). HIV-1 Vpr is in-
volved in the prevention of apoptosis in HIV-1-infected
cells (Ayyavoo et al., 1997; Conti et al., 1998; Stewart et
al., 1997; Yao et al., 1998). The low level of Vpr achieved
early postinfection due to virion-associated Vpr is likely
responsible for its antiapoptotic activity (Conti et al.,
1998). This would be consistent with recent findings that
show that when Vpr is expressed to low levels, this
activity is observed (Conti et al., 2000). The similarity in
function raises the intriguing possibility that the anti-
apoptotic activities of Vpr and PAP overlap in infected
cells. Consistently, Vpr-mediated dephosphorylation of
PAP appears to be an early event occurring as early as
6 h p.i. (Fig. 1B), when apoptosis is not yet detectable
(Yao et al., 1998) (Fig. 1D at 20 h postinfection) and when
de novo viral gene expression is not evident (Reddy and
Yin, 1999). Vpr’s effect on PAP phosphorylation status
may thus reflect the combined antiapoptotic activities of
Vpr and PAP. This idea remains to be confirmed.
The rate limiting steps for export is 39-end processing,
including cleavage and poly(A) addition; at least this is
the case for cellular RNAs (Custodio et al., 1999). Fur-
thermore, defects in mRNA export appear to cause hy-
peradenylation of de novo synthesized RNAs (Custodio
et al., 1999; Hilleren and Parker, 2001). Enhanced poly-
adenylation activity (Fig. 5) mediated by Vpr could con-
ceivably mediate a block in cellular RNA export during
HIV-1 replication. Consistently, Vpr has been shown to
cause an mRNA export defect similar to that found when
importin-b is overexpressed (Vodicka et al., 1998). While
polyadenylation is a prerequisite for HIV-1 Rev-mediated
RNA nucleocytoplasmic transport (Huang and Car-
michael, 1996) and 39-end processing is necessary for
nuclear export (Custodio et al., 1999; Eckner et al., 1991),
the data in this study could be suggestive of a model in
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RNA block in the nucleus due to hyperadenylation. Since
HIV-1 RNA poly(A) tails remain unchanged, this indicates
that HIV-1 RNA is not affected by PAP hyperactivity and
this could provide for a replicative advantage for the virus
to export its RNAs from the nucleus. The future identifi-
cation of specific cellular hyperadenylated mRNAs that
are sequestered in the nuclear compartment would sup-
port this hypothesis.
The novelty of this article is the elucidation of the
involvement of the RNA processing enzyme PAP as a
downstream effector of Vpr. Whatever the relationship
may be between PAP dephosphorylation and HIV-1 in-
fection, the implication of Vpr in this alludes to a func-
tional role in cell-cycle control, apoptosis, and/or gene
expression.
MATERIALS AND METHODS
Superinfection
Vesicular stomatitis virus G protein-pseudotyped HIV-1
particles were generated in 293T cells as described
before (Yao et al., 1998). A Vpr1, Vpr2, and a R80AVpr
mutant were included in these analyses. The description
of these clones is described in Yao et al. (1998). Jurkat
cells were infected in 100 mL RPMI medium 1 10% fetal
calf serum (FCS) at a multiplicity of infection of 10 for 4 h,
followed by extensive washing and resuspension in
fresh culture medium. At 0, 6, 12, or 20 h p.i., cells were
washed extensively in ice-cold PBS and nuclear and/or
cellular extracts were prepared as described below. All
experiments were performed in both Jurkat T and HeLa
cells. Data from Jurkat cells are shown.
DNAs
A mammalian PAP expressor was generated in the
following way. A bacterial expression plasmid, pGM10-
His6/BPAP82KCR, was generously supplied by Drs.
Georges Martin and Walter Keller (Biozentrum of Basel
University, Switzerland). Since this vector is optimized for
prokaryotic expression, the initiation codon was modi-
fied to fit the Kozak eukaryotic consensus sequence
(Kozak, 1984) using the oligomer, 59-gcacttagacgATGc-
cgtttccagttacaa. A 930-bp (XbaI/KpnI) fragment was am-
plified and was used to replace the corresponding re-
gion in pGM10-His6/BPAP82KCR to generate EukPAP. A
2230-bp XbaI/BamHI fragment was placed into pCEP
(Novagen) and used for constitutive expression from the
cytomegalovirus early promoter in transiently transfected
293T cells.
The same fragment was used to generate the tran-
scription vector, KSPAPpoly(A)1; a 2230-bp XbaI/BamHI
fragment was placed into KSII (Stratagene), and a SacI/
HindIII fragment from sp64poly(A)1 vector (Promega)
that contains a 30-nucleotide poly(A) tail was inserted
downstream to generate KSPAPpoly(A)1.Vpr was placed into pET-21c (Novagen) in-frame with a
T7 tag as described (Bachand et al., 1999) and the
poly(A) SacI/HindIII fragment was inserted downstream
of Vpr in pET-21c to generate pET-21cVprPoly(A)1. For
Vpr and PAP RNA synthesis, in vitro transcription was
performed in the presence of the cap analogue to pre-
pare polyadenylated, capped RNAs for oocyte injections
described below.
Transient transfections
293T cells were cultured in DMEM with 10% FCS and
antibiotics. Calcium phosphate coprecipitation was used
for transfections. The wild-type CMV-Vpr expressor used
here was described previously (Yao et al., 1998). At 36 h,
cells were pulsed with 300 mCi 35S-TransLabel (ICN) for
12 h. Cells were then lysed in RIPA buffer (0.15 M NaCl,
10 mM Tris, pH 7.4, 1 mM EDTA, 0.01% SDS, 0.2% NP-40,
0.05% sodium deoxycholate) and sequentially immuno-
precipitated with 2 mL anti-PAP (Colgan et al., 1996), and
anti-Vpr. For mock lanes, 293T cells were transfected
with either EukPAP or SVCMV-Vpr followed by immuno-
precipitation with preimmune rabbit serum. Immunopre-
cipitates were run on SDS–PAGE gels (7% for PAP and
12% for Vpr), dried, and exposed to film.
Cell-cycle and Annexin V apoptosis analyses were
performed at 20 h postinfection as described previously
(Yao et al., 1998).
Oocyte injections
Stage 6 oocytes were harvested as described (Coady
et al., 1998) and injected with 500 ng PAP, Vpr, or both
PAP and Vpr RNA (polyadenylated and capped as de-
scribed above), or water as control. Oocytes were main-
tained in Barth’s [90 mM NaCl, 3 mM KCl, 0.82 mM
MgSO4, 0.41 mM CaCl2, 0.33 mM Ca(NO3)2, 5 mM
HEPES, pH 7.6]. At 12 h, the oocytes were induced to
mature with the use of 25 mM progesterone (Sigma). At
36 h, oocytes were harvested in phosphate-buffered sa-
line and homogenized using an Eppendorf pestle. Lipids
and membranes were removed by extraction with 1,1,2-
trichlorotrifluorethane. RIPA (400 mL) was added to the
lysate, and PAP and Vpr were immunoprecipitated as
described above. The oocyte injection experiments have
been optimized to allow for maximal Vpr expression at
the time of homogenization (36–44 h postinjection; A. J.
Mouland and M. Coady, unpublished observations).
Nuclear and whole-cell extracts
Nuclear extracts were prepared from 100–150 3 106
cells for each infection by a modified nuclear extract
lysolecithin method (Zerivitz and Akusjarvi, 1989). Briefly,
cells were washed twice with PBS and resuspended in
two packed cell volumes (PCV) of Buffer A [0.25 M su-
crose, 20 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl2,
0.5 mM dithiothreitol (DTT), 0.5 mM spermidine, 0.15 mM
328 MOULAND ET AL.spermine] and then resuspended at 1 3 108 cells/mL in
Buffer A and left at room temperature for 5 min. Lysolec-
ithin (Sigma) was added to 400 mg/mL and the cell
suspension was mixed by gentle swirling. Two volumes
of Buffer B (Buffer A 1 3% bovine serum albumin) were
added and the nuclei were pelleted at 4°C at 1000 g for
30 s. The supernatant was discarded and the nuclear
pellet was spun at 25,000 g for 2 min. Buffer C [20 mM
HEPES, pH 7.9, 25% glycerol, 0.42 NaCl, 1.5 mM MgCl2,
0.2 mM EDTA, 0.5 mM DTT, 0.5 mM phenylmethylsulfo-
nylfluoride (PMSF)] was added to 109 cells/3 mL and
homogenized using a 23-G needle. The suspension was
stirred on ice for 30 min and then centrifuged at 25,000 g
for 30 min. The supernatant was dialyzed overnight
against Buffer D (20 mM HEPES, pH 7.9, 20% glycerol, 0.1
M KCl, 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF) with
three buffer changes. The dialysate was clarified by
centrifugation at 25,000 g for 20 min and snap frozen in
liquid nitrogen until analysis. Alternatively, whole-cell ex-
tracts (Fig. 1B) were prepared by sonication as described
previously (Colgan et al., 1998).
Protein quantitation, Western analysis, and
polyadenylation assays
Nuclear extracts were thawed on ice and protein con-
centration was quantitated by the method of Lowrie us-
ing the Bio-Rad Protein Assay Kit. For Western analysis of
PAP in nuclear extracts, polyclonal and affinity-purified
antibodies [generous gifts from Dr. James Manley (Co-
lumbia University, NY) and Dr. Walter Keller (Biozentrum,
Switzerland)] were used to probe blots that contained
cell extracts from Vpr1-, Vpr2-, R80AVpr-superinfected
cells. Controls included nuclear extracts from nocoda-
zole-treated (0.43 mM) cells in which PAP becomes hy-
perphosphorylated and from mock-infected cells. Reve-
lation of PAP was performed by a sensitive luminol-
based chemiluminescence method at pH 10.5 (Yakunin
and Hallenbeck, 1998).
Nonspecific polyadenylation assays were performed
essentially as described (Colgan et al., 1996) with a few
modifications. Briefly, at 20 h p.i., nuclear extracts were
prepared as above from superinfected and control cells
and diluted 23 in 20 mM HEPES, pH 7.9, 0.2 mM EDTA,
0.5 mM DTT, 25 mM NaCl, 10% glycerol, and 0.5 mM
PMSF. This was spun for 10 min in a microcentrifuge and
loaded onto an 18 3 1 cm gel filtration column containing
Ultragel AcA (MW, 20,000–300,000; IBF Biotechnics,
France; kindly supplied by Dr. P. Hallenbeck, Universite´
de Montre´al). Fractions (250 mL) were collected and the
PAP elution profile (about 97 kDa) was determined em-
pirically by Western blot analysis and with the use of
prestained molecular weight markers (Bio-Rad). Peak
PAP fractions from each experimental condition were
kept and dialyzed against the above buffer, except 50
mM ammonium sulfate replaced NaCl. A 10-mL aliquotwas used directly in polyadenylation assays as de-
scribed below. In some experiments, four fractions sur-
rounding the peak fraction (peak22, 21, peak, peak11,
12) were included in this assay.
For this assay a radiolabeled RNA substrate is used
and changes in RNA length is due to PAP activity in the
extract. An SV40 RNA template is used as described
before (Colgan et al., 1996) and generated in a standard
in vitro transcription reaction with 50 mCi of 32P-labeled
UTP (1000 Ci/mmol; ICN). Nuclear extract (10 mL) was
combined with polyvinyl alcohol to 2%, 1 mM MnCl2, 1
mM ATP, 20 mM creatine phosphate, and 25,000 cpm
32P-SV40 RNA in a total volume of 20 mL and incubated at
30°C for 60 min. The RNA products were phenol-ex-
tracted twice, followed by a chloroform extraction, etha-
nol precipitated using 60 mg glycogen as a carrier, and
resolved on a 5% denaturing polyacrylamide/8 M urea
gel with 13 Tris–borate–EDTA as the running buffer.
Gels were directly exposed to film. Peak21, 22, 11, 12
fractions were tested as above and reflected the PAP
activities in the peak fractions as shown below (not
shown).
RNA stability measurements
Jurkat cells were superinfected as described above
using Vpr1 or Vpr2 HIV-1 VSV-G-pseudotyped virus. At
12 h p.i., cells were treated with transcription inhibitor,
Dactinomycin (Sigma; 25 mM) for 12 h, followed by ex-
tensive washing (time 0). At this concentration 99% of
RNA synthesis as measured by 3H-uridine labeling is
inhibited (not shown). At 0, 3, and 6, 12 h (in some
experiments), cytosolic RNA was isolated (Yao et al.,
1998) and fractionated through a formaldehyde/agarose
gel. The RNA was transferred to nylon membrane and
probed with a 32P-labeled DNA fragment to the HIV-1
RNA leader and glyceraldehyde dehydrogenase
(GAPDH) as described before (Yao et al., 1998). The 28S
and 18S rRNAs served as molecular weight markers.
Autoradiographic signals were quantitated by a Molec-
ular Dynamics phosphorimager. HIV-1 RNA levels were
expressed by relating the signal obtained for each HIV-1
RNA species and related to the signal obtained for
GAPDH in each lane. The signal at time 0 was set to
100%.
HIV-1 poly(A) tail length determinations
Cytosolic RNA from Vpr2, Vpr1, and mock-superin-
fected cells was isolated and used in an RNAseH pro-
tocol to determine poly(A) length of HIV-1 transcripts.
Total RNA (8 mg) was incubated with 1.3 mg antisense
HIV-1 antisense oligomer [25-mer; 59 TGACATCGAGCT-
TGCTACAAGGGAC-39, targeted to nt 8953–8977 of
HxBc2 (Ratner et al., 1985), 178 nt upstream of the 39
polyadenylation signal of HIV-1] in 28 mM MgCl2, 25 mM
KCl, 0.5 mM EDTA, 20 mM Tris, pH 7.5 for 5 min at 65°C
329HIV-1 Vpr AND POLY(A) POLYMERASE PHOSPHORYLATIONand then allowed to cool to room temperature for 10 min.
RNAse H (2 U) was added and incubation proceeded for
an additional 45 min. This was followed by phenol:chlo-
roform extractions and ethanol precipitation and resolu-
tion on a 2% formaldehyde/agarose gel and transfer to
nylon membrane, as above. Molecular weight RNA mark-
ers were visualized by ethidium bromide staining of the
gel fragment. The membrane was hybridized with a 32P-
labeled probe, generated by 59-end labeling by T4
polynucleotide kinase of an 80-bp DNA that includes the
TAR sequence to the HindIII site immediately down-
stream of the HIV-1 polyadenylation signal. In control
experiments the poly(A) tail lengths of GAPDH and actin
mRNAs were determined (not shown).
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